Earnings summaries and quarterly performance for BeOne Medicines.
Executive leadership at BeOne Medicines.
Board of directors at BeOne Medicines.
AR
Alessandro Riva
Detailed
Director
AH
Anthony Hooper
Detailed
Director
CS
Corsee Sanders
Detailed
Director
MD
Margaret Dugan
Detailed
Director
MG
Michael Goller
Detailed
Director
OB
Olivier Brandicourt
Detailed
Director
QY
Qingqing Yi
Detailed
Director
RK
Ranjeev Krishana
Detailed
Lead Independent Director
SS
Shalini Sharp
Detailed
Director
XW
Xiaodong Wang
Detailed
Director
Research analysts who have asked questions during BeOne Medicines earnings calls.
Andrew Berens
Leerink Partners
5 questions for ONC
Also covers: AGIO, ARVN, BGNE +6 more
JF
Jessica Fye
JPMorgan Chase & Co.
5 questions for ONC
Also covers: ALKS, ALNY, AMRN +23 more
Ziyi Chen
Goldman Sachs & Co.
5 questions for ONC
Also covers: BGNE, LEGN, ZLAB
RB
Reni Benjamin
Citizens JMP Securities
4 questions for ONC
Also covers: ALLO, BCAB, BGNE +7 more
Sean Laaman
Morgan Stanley & Co.
4 questions for ONC
Also covers: ACAD, ARGX, AXSM +8 more
YN
Yigal Nochomovitz
Citigroup Inc.
4 questions for ONC
Also covers: ALDX, APLS, ARCT +22 more
DS
Dingding Shi
Jefferies
3 questions for ONC
Also covers: ADCT, ASND, AUTL +6 more
Michael Schmidt
Guggenheim Securities
3 questions for ONC
Also covers: ADAP, ADCT, ARVN +19 more
Gregory Renza
RBC Capital Markets
1 question for ONC
Also covers: ACAD, ADCT, AGIO +12 more
Kelly Shi
Jefferies
1 question for ONC
Also covers: ADCT, AGEN, ALDX +17 more
TC
TD Cowen Analyst
TD Cowen
1 question for ONC
UA
Unknown Analyst
Morgan Stanley
1 question for ONC
Also covers: ATEYY, BDORY, BSBR +19 more
YW
Yaron Werber
TD Cowen
1 question for ONC
Also covers: ALEC, AMGN, ARGX +14 more
Recent press releases and 8-K filings for ONC.
Oncolytics Biotech Shareholders Approve Continuance, Domestication, and 2026 Incentive Award Plan
ONC
Proxy Vote Outcomes
Executive Compensation
- Oncolytics Biotech Inc. held a special meeting of shareholders on January 15, 2026, where Kirk Look, CFO, served as Chair.
- Shareholders approved the Continuance Resolution, which will move the company's jurisdiction from Alberta to British Columbia.
- The Domestication Resolution, allowing the company to continue out of British Columbia and domesticate to Nevada, was also approved.
- The proposed 2026 Incentive Award Plan received shareholder approval.
Jan 15, 2026, 3:00 PM
Oncolytics Biotech provides update on pelareorep clinical development and market opportunities
ONC
New Projects/Investments
- Oncolytics Biotech's pelareorep has demonstrated significant clinical proof of concept across targeted indications, including 2L mCRC, ≥2L SCAC, and 1L mPDAC, showing improvements in overall survival, progression-free survival, and objective response rates compared to standard of care benchmarks.
- The company's clinical development pipeline includes a KRAS-mutant mCRC study launching in 1H 2026, a potential single-arm pivotal study for ≥2L SCAC launching in Q3 2026, and US sites opening for newly diagnosed PDAC in 1H 2026.
- Pelareorep targets substantial market opportunities, with an estimated $20 billion total addressable market for 2L Metastatic Colorectal Cancer and $3 billion for 1L Metastatic Pancreatic Ductal Adenocarcinoma.
- Pelareorep has been evaluated in over 1,200 patients across multiple cancer indications in more than 20 studies, demonstrating a generally well-tolerated safety profile with no maximum tolerated dose identified.
Jan 14, 2026, 12:00 PM
BeOne Medicines Highlights Global Oncology Leadership and Financial Strength at J.P. Morgan Conference
ONC
Product Launch
New Projects/Investments
Guidance Update
- BeOne Medicines presented its global leadership in oncology at the 44th J.P. Morgan Annual Health Conference on January 13, 2026, emphasizing its strong position in B-cell malignancies.
- Key product highlights include BRUKINSA®, a global leader in BTK inhibitors, and recent regulatory approvals for sonrotoclax (a next-generation BCL2 inhibitor) on December 30.
- The company anticipates significant data catalysts in 2026, including uMRD results from the Phase 3 CELESTIAL study and pivotal results from the Phase 2 study of BGB-16673 in relapsed/refractory CLL.
- BeOne Medicines maintains a strong financial profile, reporting over $350 million in free cash flow in Q3 2025 and holding over $4 billion in cash.
Jan 13, 2026, 5:41 PM
BeOne Medicines Präsentation auf der J.P. Morgan Healthcare Conference
ONC
New Projects/Investments
- BeOne Medicines showcased its global leadership in oncology and hematology at the 44th J.P. Morgan Healthcare Conference, highlighting key products like BRUKINSA® and pipeline assets Sonrotoclax (which received first global approvals on December 30) and BGB-16673.
- The company reported a strong financial position with over $350 million in free cash flow in Q3 2025 and over $4 billion in cash, enabling investments in future growth and global reach while maintaining profitability.
- BeOne emphasized its unique global clinical development "Superhighway" and plans to advance 8 to 10 new molecular entities (NMEs) into clinical phases annually starting in 2026, with key clinical trial results for Zanubrutinib/Sonrotoclax and BGB-16673 expected in 2026.
Jan 13, 2026, 5:36 PM
BeOne Medicines Highlights Global Oncology Leadership and Financial Strength at J.P. Morgan Conference
ONC
New Projects/Investments
Guidance Update
Product Launch
- BeOne Medicines presented at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026, outlining its global oncology leadership and strong financial profile.
- The company highlighted its foundational hematology assets, including BRUKINSA, which is the global revenue leader among BTK inhibitors, and sonrotoclax, which received its first global regulatory approvals on December 30.
- BeOne anticipates significant clinical trial results in 2026 for the investigational combination of BRUKINSA and sonrotoclax (Phase 3 CELESTIAL trial) and for BGB-16673 (potentially pivotal Phase 2 trial).
- Financially, BeOne generated more than $350 million in free cash flow in Q3 2025 and holds over $4 billion in cash on hand, with expectations to maintain profitability in 2026 and beyond.
Jan 13, 2026, 11:00 AM
BeOne Medicines Receives FDA Accelerated Approval Designation for BGB-B2033
ONC
Product Launch
New Projects/Investments
- BeOne Medicines received Accelerated Approval designation from the U.S. FDA for BGB-B2033 on December 18, 2025.
- BGB-B2033 is a GPC3x4-1BB bispecific antibody designed to treat adult patients with hepatocellular carcinoma (HCC) who have experienced disease progression during or after prior systemic treatment.
- This designation highlights the potential of BGB-B2033 to address a significant unmet medical need in advanced HCC, a disease for which patients currently have limited treatment options.
Dec 18, 2025, 9:28 PM
BeOne Medicines Receives FDA Fast Track Designation for BGB-B2033
ONC
- BeOne Medicines (Nasdaq: ONC) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for its BGB-B2033.
- BGB-B2033 is a bispecific antibody intended for the treatment of adult patients with hepatocellular carcinoma (HCC) whose disease has progressed during or after previous systemic treatment.
- The FDA's decision reflects the potential of BGB-B2033 to address a high unmet medical need in advanced HCC, where patients face limited treatment options.
- BeOne is currently conducting a global Phase 1 clinical trial (NCT06427941) to evaluate the safety and anti-tumor activity of BGB-B2033, both alone and in combination with TEVIMBRA®.
Dec 18, 2025, 9:26 PM
BeOne Medicines' BGB-B2033 Receives FDA Fast Track Designation
ONC
New Projects/Investments
- BeOne Medicines' BGB-B2033 has been granted FDA Fast Track designation for the treatment of adult hepatocellular carcinoma (HCC) patients whose disease has progressed after prior systemic therapy.
- BGB-B2033 is a bispecific antibody designed to target GPC3 and 4-1BB, addressing a high unmet medical need in late-stage HCC, where current treatment options are limited.
- The company is currently conducting a global multi-center Phase 1 clinical trial (NCT06427941) to evaluate BGB-B2033 as a monotherapy and in combination with TEVIMBRA® (tislelizumab).
Dec 18, 2025, 9:19 PM
BeOne Medicines Receives FDA Fast-Track Status for BGB-B2033
ONC
- BeOne Medicines Ltd. (ONC) announced that the U.S. Food and Drug Administration (FDA) has granted Fast-Track status for its bispecific antibody, BGB-B2033.
- BGB-B2033 is intended for the treatment of adult patients with hepatocellular carcinoma (HCC) whose disease has progressed during or after previous systemic treatment.
- The FDA awards Fast-Track status to therapies with the potential to address unmet medical needs in serious or life-threatening conditions, reflecting the promising profile of BGB-B2033 in advanced HCC.
- BeOne is currently conducting a global, multicenter Phase 1 clinical trial (NCT06427941) to investigate the safety and anti-tumor activity of BGB-B2033, both alone and in combination with TEVIMBRA® (Tislelizumab).
Dec 18, 2025, 9:02 PM
BeOne Medicines receives FDA Fast Track status for BGB-B2033
ONC
Product Launch
New Projects/Investments
- BeOne Medicines Ltd. (Nasdaq: ONC) announced that the U.S. Food and Drug Administration (FDA) granted Fast Track status to its bispecific antibody, BGB-B2033.
- BGB-B2033 is intended for the treatment of adult patients with hepatocellular carcinoma (HCC) who have experienced disease progression during or after previous systemic treatment.
- The FDA Fast Track status highlights the drug's potential in an area with a significant unmet medical need.
Dec 18, 2025, 7:07 PM
Quarterly earnings call transcripts for BeOne Medicines.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more